keyword
MENU ▼
Read by QxMD icon Read
search

Pcnsl

keyword
https://www.readbyqxmd.com/read/29152083/programmed-cell-death-1-expression-is-associated-with-inferior-survival-in-patients-with-primary-central-nervous-system-lymphoma
#1
Hyunsoo Cho, Se Hoon Kim, Soo-Jeong Kim, Jong Hee Chang, Woo-Ick Yang, Chang-Ok Suh, Yu Ri Kim, Ji Eun Jang, June-Won Cheong, Yoo Hong Min, Jin Seok Kim
Programmed cell death 1 (PD-1) and its ligands PD-L1/PD-L2 have been shown to mediate immune evasion in various cancers, but their prognostic implications in patients with primary central nervous system lymphoma (PCNSL) are poorly understood. Therefore, we analyzed 76 PCNSL patients at initial diagnosis who were treated homogenously with high-dose methotrexate-based chemotherapy, and evaluated the prognostic roles of high immunohistochemical PD-1, PD-L1, and PD-L2 expression. The cut-off values for high PD-1 (≥ 70 cells/high power field [HPF]), PD-L1 (≥ 100 cells/HPF), and PD-L2 (≥ 100 cells/HPF) were determined by the area under the receiver operating characteristic curve...
October 20, 2017: Oncotarget
https://www.readbyqxmd.com/read/29151258/clinical-significance-of-disease-specific-myd88-mutations-in-circulating-dna-in-primary-central-nervous-system-lymphoma
#2
Keiichiro Hattori, Mamiko Sakata-Yanagimoto, Yasuhito Suehara, Yasuhisa Yokoyama, Takayasu Kato, Naoki Kurita, Hidekazu Nishikii, Naoshi Obara, Shingo Takano, Eiichi Ishikawa, Akira Matsumura, Yuichi Hasegawa, Shigeru Chiba
Recent sequencing studies demonstrated the MYD88 L265P mutation in more than 70% of primary central nervous system lymphomas (PCNSL), and the clinical significance of this mutation has been proposed as diagnostic and prognostic markers in PCNSL. On the other hand, mutational analyses using cell-free DNAs have been reported in a variety of systemic lymphomas. To investigate how sensitively the MYD88 L265P mutation can be identified in cell-free DNA from PCNSL patients, we performed droplet digital PCR (ddPCR) and targeted deep sequencing (TDS) in consecutive 14 PCNSL patients from whom paired tumor-derived DNA and cell-free DNA was available at diagnosis...
November 19, 2017: Cancer Science
https://www.readbyqxmd.com/read/29143277/myo-inositol-concentration-in-mr-spectroscopy-for-differentiating-high-grade-glioma-from-primary-central-nervous-system-lymphoma
#3
Hiroaki Nagashima, Takashi Sasayama, Kazuhiro Tanaka, Katsusuke Kyotani, Naoko Sato, Masahiro Maeyama, Masaaki Kohta, Junichi Sakata, Yusuke Yamamoto, Kohkichi Hosoda, Tomoo Itoh, Ryohei Sasaki, Eiji Kohmura
It is sometimes difficult to distinguish gliomas from other tumors on routine imaging. In this study, we assessed whether 3-T magnetic resonance spectroscopy (MRS) with LCModel software might be useful for discriminating glioma from other brain tumors, such as primary central nervous system lymphomas (PCNSLs) and metastatic tumors. A total of 104 cases of brain tumor (66 gliomas, 20 PCNSLs, 6 metastatic tumors, 12 other tumors) were preoperatively investigated with short echo time (35 ms) single-voxel 3-T MRS...
November 15, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/29128836/characterization-of-liposome-containing-spions-conjugated-with-anti-cd20-developed-as-a-novel-theranostic-agent-for-central-nervous-system-lymphoma
#4
S Saesoo, S Sathornsumetee, P Anekwiang, C Treetidnipa, P Thuwajit, S Bunthot, W Maneeprakorn, L Maurizi, H Hofmann, Ruktanonchai Uracha Rungsardthong, N Saengkrit
Despite advances in neuroscience cancer research during the past decades, the survival of cancer patients has only marginally improved and the cure remains unlikely. The blood-brain barrier (BBB) is a major obstacle protecting the entry of therapeutic agents to central nervous system, especially for primary central nervous system lymphoma (PCNSL). Thus, the use of small nanoparticle as a drug carrier may be new strategies to overcome this problem. In this study, we fabricated liposome consisting of superparamagnetic iron oxide nanoparticles (SPIONs) functionalized with anti-CD20 (Rituximab; RTX)...
November 8, 2017: Colloids and Surfaces. B, Biointerfaces
https://www.readbyqxmd.com/read/29113178/immunohistochemical-profile-and-prognostic-significance-in-primary-central-nervous-system-lymphoma-analysis-of-89-cases
#5
Jing Liu, Yaming Wang, Yuantao Liu, Zhe Liu, Qu Cui, Nan Ji, Shengjun Sun, Bingxu Wang, Yajie Wang, Xuefei Sun, Yuanbo Liu
The majority of primary central nervous system lymphomas (PCNSLs) are diffuse large B cell lymphoma, characterized by poor prognosis. In the present study, the expression of cluster of differentiation (CD)10, B cell lymphoma (BCL)-6, multiple myeloma-1 (MUM-1), BCL-2, CD138 and Ki-67 was analyzed by immunohistochemistry in 89 Chinese PCNSL cases, and the potential prognostic significance was evaluated. CD10, BCL-6, MUM-1, BCL-2 and CD138 were positive in 16.9 (15/89), 51.7 (46/89), 92.1 (82/89), 73.3 (63/86) and 0% (0/65) of all cases, respectively...
November 2017: Oncology Letters
https://www.readbyqxmd.com/read/29110994/spinal-cord-involvement-in-primary-cns-lymphoma
#6
Arunmozhi Maran Elavarasi, Deepa Dash, Anand R Warrier, Rohit Bhatia, Lalit Kumar, Deepali Jain, Manjari Tripathi
LETM is a common syndrome and the diagnosis of CNS lymphoma is not usually considered in the list of differentials. Primary CNS lymphoma can present as longitudinally extensive transverse myelopathy. Failure to suspect and evaluate leads to delay in diagnosis and treatment. PCNSL may be non contrast enhancing on gadolinium enhanced MRI. CSF analysis should be done preferably before starting corticosteroids as it is usual practice in treatment of transverse myelitis, as steroids may lead to transient improvement and mask the correct diagnosis...
October 27, 2017: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/29070116/-effect-of-b-cell-differentiation-markers-on-the-prognosis-of-primary-central-nervous-system-lymphoma
#7
Xiang-Lei Chen, Xiao-Yun Li, Wei Wang
OBJECTIVE: To investigate the value of B-cell differentiation markers in prognosis evaluation of 119 patients with primary CNS lymphoma(PCNSL). METHODS: The expressions of BCL-2, BCL-6, CD10 and MUM1/IRF4 protein were determined by immunohistochemistry, and their relationship with the prognosis of primary central nervous system lymphoma was analyzed. RESULTS: Univariate analysis showed that BCL-6 positive means shorter PFS (P=0.047) and OS (P=0...
October 2017: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/29070115/-curative-efficacy-of-high-dose-mtx-combined-with-rituxan-for-treatment-primary-cns-lymphoma
#8
Kun Mou, Wei-Wei Gu, Cui-Hua Gu, Jiu-De Qi
OBJECTIVE: To explore the curative efficacy of methotrexate(MTX) combined with rituxan for treating patients with primary central nervous system(CNS) lymphoma. METHODS: One hundred patients with primary CNS lymphoma in our hospital were randomly divided into targeted treatment group(50 cases) and traditional treatment group (50 cases). Targeted treatment group adopted the therapy of high-dose methotrexate combined with rituxan, the traditional treatment group adopted the high-dose methotrexate combined with whole brain radiotherapy...
October 2017: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/29043230/advances-in-the-treatment-of-newly-diagnosed-primary-central-nervous-system-lymphomas
#9
REVIEW
Liren Qian, Ciprian Tomuleasa, Ioan-Alexandru Florian, Jianliang Shen, Ioan-Stefan Florian, Mihnea Zdrenghea, Delia Dima
Primary central nervous system lymphoma (PCNSL) is a type of highly invasive non-Hodgkin lymphoma. With a growing number of organ transplantation and immunosuppressant therapy, the incidence of PCNSL has been growing rapidly in recent years, which is attributed to the increased incidence of HIV/AIDS, a prominent risk factor for developing PCNSL. The rising rate of PCNSL incidence is the highest among the intracranial tumors. In the past 20 years, dozens of clinical trials related to PCNSL have been registered, but adequate therapeutics are still challenging...
September 2017: Blood Research
https://www.readbyqxmd.com/read/29036697/the-elderly-left-behind-changes-in-survival-trends-of-primary-central-nervous-system-lymphoma-over-the-past-four-decades
#10
Joe S Mendez, Quinn T Ostrom, Haley Gittleman, Carol Kruchko, Lisa M DeAngelis, Jill S Barnholtz-Sloan, Christian Grommes
Background: There has been significant improvement in treatment outcomes of Primary Central Nervous System Lymphoma (PCNSL) at specialized centers over the past several decades; however, it is unclear if these changes have translated to benefits in the general population. Methods: In this study, we utilized two national databases to examine survival trends over time for PCNSL (Central Brain Tumor Registry of the United States (CBTRUS, 2000 - 2013) and 18 Surveillance, Epidemiology, and End Results (SEER, 1973 - 2013) registries)...
October 3, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28984175/primary-central-nervous-system-lymphoma-retrospective-analysis-of-34-cases-in-a-single-centre
#11
Huafeng Wang, Ming Wang, Juying Wei, Lei Wang, Liping Mao, Jie Jin
Objective To retrospectively analyse outcomes in patients with primary central nervous system lymphoma (PCNSL), which is a malignant CNS non-Hodgkin's lymphoma with a poor prognosis. Methods This study retrospectively analysed the treatment and outcomes of patients with PCNSL, which were divided into two groups: surgery (S) group and surgery/biopsy+chemotherapy (SC) group. The latter group was further subdivided into four cohorts based on the treatment regimen: cyclophosphamide, epidoxorubicin, vincristine and prednisone (CHOP), high-dose methotrexate (HDM)+dexamethasone+rituximab (HDM+D+R), HDM+D+temozolomide (HDM+D+T), and HDM+D+R+T...
January 1, 2017: Journal of International Medical Research
https://www.readbyqxmd.com/read/28983970/increasing-incidence-of-primary-cns-lymphoma-but-no-improvement-in-survival-in-sweden-2000-2013
#12
S Eloranta, E Brånvall, F Celsing, K Papworth, M Ljungkvist, G Enblad, K E Smedby
OBJECTIVES: This study aims to characterize the epidemiology of immunocompetent PCNSL diagnosed 2000 to 2013 in Sweden. METHODS: Cases were identified in the population-based Swedish Lymphoma Register. Incidence per 100,000 person-years and 95% confidence intervals (CI) were calculated, and PCNSL-specific survival was estimated using relative survival. Tests for temporal trends were performed using Poisson regression. Population incidence of all brain tumors was retrieved for comparison...
October 6, 2017: European Journal of Haematology
https://www.readbyqxmd.com/read/28982883/programmed-cell-death-ligand-1-expression-in-primary-central-nervous-system-lymphomas-a-clinicopathological-study
#13
Azusa Hayano, Yoshihiro Komohara, Yasuo Takashima, Hiroto Takeya, Jumpei Homma, Junya Fukai, Yasuo Iwadate, Koji Kajiwara, Shin Ishizawa, Hiroaki Hondoh, Ryuya Yamanaka
BACKGROUND/AIM: Programmed cell death ligand 1 (PD-L1)/programmed cell death 1 (PD-1) have been shown to predict response to PD-L1/PD-1-targeted therapy. We analyzed PD-L1 expression in primary central nervous system lymphomas (PCNSLs). MATERIALS AND METHODS: PD-L1 protein and mRNA expression were evaluated in 64 PCNSL tissue samples. IFN-γ, IL-10, CD4, and CD8 mRNA expression was also evaluated. RESULTS: PD-L1 protein was detected in tumor cells in 2 (4...
October 2017: Anticancer Research
https://www.readbyqxmd.com/read/28982392/lymphomatosis-cerebri-a-rare-variant-of-primary-central-nervous-system-lymphoma-and-mr-imaging-features
#14
Hui Yu, Bo Gao, Jing Liu, Yong-Cheng Yu, Mark S Shiroishi, Ming-Ming Huang, Wen-Xiu Yang, Zhi-Zhong Guan
BACKGROUND: Lymphomatosis cerebri (LC) is a rare variant of primary central nervous system lymphoma (PCNSL), characterized by diffuse infiltration without the formation of a discrete mass. The diagnosis of LC is a challenge because the imaging findings are atypical for lymphoma. The purpose of present study is to investigate MRI characteristics and clinical features of LC and potentially facilitate an early and accurate diagnosis of this often-missed disease. METHODS: Seven patients (average 44 years, 19-58 years) with LC proved basing on MRI and histology were retrospectively reviewed the clinical data and cerebral MR imaging findings...
October 5, 2017: Cancer Imaging: the Official Publication of the International Cancer Imaging Society
https://www.readbyqxmd.com/read/28981733/prognostic-factors-for-primary-central-nervous-system-lymphomas-treated-with-high-dose-methotrexate-based-chemo-radiotherapy
#15
Jeunghun Lee, Yukiko Shishido-Hara, Kaori Suzuki, Saki Shimizu, Keiichi Kobayashi, Hiroshi Kamma, Yoshiaki Shiokawa, Motoo Nagane
Background: Primary central nervous system lymphoma (PCNSL) remains an aggressive and refractory tumor despite high-dose methotrexate-based chemo-radiotherapy. Age and performance status have been shown to be important clinical prognostic factors, however others, especially molecular factors, affecting the prognosis are still uncertain. Methods: We investigate clinical, neuroimaging and immunohistochemical data in tissue from 41 PCNSL patients treated primarily with methotrexate-based chemo-radiotherapy and evaluate the influence of potential prognostic factors on clinical outcome as well as correlation among these factors...
October 1, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28981729/immunochemotherapy-using-rituximab-rtx-and-high-dose-methotrexate-hd-mtx-an-evaluation-of-the-addition-of-rtx-to-hd-mtx-in-recurrent-primary-central-nervous-system-lymphoma-pcnsl
#16
Yasuji Miyakita, Makoto Ohno, Masamichi Takahashi, Yoshihiro Muragaki, Hitoshi Katai, Yoshitaka Narita
Background: There is increasing evidence that MTX-based chemotherapy is superior to HD-MTX alone. Rituximab (RTX) is effective in a variety of B-cell lymphomas and may enter the brain. The purpose of this study is to evaluate the addition of RTX to HD-MTX in recurrent primary central nervous system lymphoma (PCNSL). Methods: Patients diagnosed with recurrent PCNSL at our institution between 2004 and 2009 were treated with HD-MTX (3.5-5.5 g/m2) every 2 weeks. From 2010, RTX (375 mg/m2) was administered every 2 weeks along with HD-MTX...
October 1, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28973509/whole-brain-radiation-dose-reduction-for-primary-central-nervous-system-lymphoma-patients-who-achieved-partial-response-after-high-dose-methotrexate-based-chemotherapy
#17
Jun S Park, Do Hoon Lim, Yong Chan Ahn, Won Park, Seok Jin Kim, Won Seog Kim, Kihyun Kim
Background: The whole brain radiotherapy (WBRT) dose for primary central nervous system lymphoma (PCNSL) patients who achieved complete response after induction chemotherapy was recently reduced to 23.4 Gy, but the optimal radiation dose for patients who achieved partial response (PR) is controversial. The aim of this study was to investigate the feasibility of reduced-dose WBRT for patients who achieved PR. Method: We retrospectively reviewed the medical records of PCNSL patients who were treated with high-dose methotrexate based chemotherapy...
November 1, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28973119/optic-nerve-infiltration-in-primary-central-nervous-system-lymphoma
#18
Guido Ahle, Valérie Touitou, Nathalie Cassoux, Marie Bouyon, Catherine Humbrecht, Hélène Oesterlé, Alexander Baraniskin, Carole Soussain, Ludovic Nguyen-Them, Claude Gaultier, Khê Hoang-Xuan, Caroline Houillier
Importance: Visual impairment in primary central nervous system lymphoma (PCNSL) is caused mostly by intraocular lymphomatous involvement (vitritis and retinal infiltration), whereas optic nerve infiltration (ONI) is a rare condition. Objective: To describe the clinical presentation of ONI, its imaging characteristics, and outcome. Design, Setting and Participants: A total of 752 patients diagnosed with PCNSL were retrospectively identified from the databases of 3 French hospitals from January 1, 1998, through December 31, 2014...
November 1, 2017: JAMA Neurology
https://www.readbyqxmd.com/read/28962961/natalizumab-associated-primary-central-nervous-system-lymphoma
#19
REVIEW
Menarvia Nixon, Richard P Menger, Piyush Kalakoti, Jai Deep Thakur, Rimal H Dossani, Kanika Sharma, Anil Nanda, Bharat Guthikonda
Natalizumab, a selective adhesion molecule inhibitor binding to α-4 subunit of integrin, has emerged to be an effective immuno-modulator especially in the treatment of relapsing-remitting Multiple Sclerosis and Crohn's disease. Literature documenting the development of progressive multifocal leukoencephalopathy from its use is widely available. However, only handful of reports cites the development of a more concerning pathology, primary CNS lymphoma (PCNSL) from its administration, thereby triggering a debate on a possible causal association...
September 26, 2017: World Neurosurgery
https://www.readbyqxmd.com/read/28959507/a-regional-multicenter-retrospective-analysis-of-patients-with-primary-central-nervous-system-lymphoma-diagnosed-from-2000-2012-treatment-patterns-and-clinical-outcomes
#20
Eric C Burton, Beatrice Ugiliweneza, Murali K Kolikonda, Tanuj Saaraswat, Shiao Woo, Maxwell Boakye, Lennea Coombs, Renato LaRocca, Aaron Spalding
Introduction Primary central nervous system lymphoma (PCNSL) is a rare tumor without a well-defined standard of care. For immunocompetent patients, therapeutic regimens have largely evolved from treatment with whole-brain radiation therapy (WBRT) to treating initially with systemic chemotherapy regimens that include high-dose (HD) methotrexate (MTX) with or without WBRT. Looking at population-based treatment trends may help define which therapies are most effective. This study was conducted to determine treatment patterns and outcomes for patients with PCNSL in the Louisville, KY metropolitan area during the period 2000 to 2012...
July 25, 2017: Curēus
keyword
keyword
59503
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"